These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 7715908

  • 1. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
    Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Meregalli S, Fossati V, Fumagalli L, Brivio F, Tancini G.
    Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
    [Abstract] [Full Text] [Related]

  • 2. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
    Lissoni P, Barni S, Fossati V, Ardizzoia A, Cazzaniga M, Tancini G, Frigerio F.
    Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000 May; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 4. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
    Cerea G, Vaghi M, Ardizzoia A, Villa S, Bucovec R, Mengo S, Gardani G, Tancini G, Lissoni P.
    Anticancer Res; 2003 May; 23(2C):1951-4. PubMed ID: 12820485
    [Abstract] [Full Text] [Related]

  • 5. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R.
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
    Lissoni P, Brivio F, Fumagalli L, Di Fede G, Brera G.
    In Vivo; 2005 Jan; 19(6):1077-80. PubMed ID: 16277025
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Jan; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 8. A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
    Barni S, Lissoni P, Paolorossi F, Crispino S, Archili C, Tancini G.
    Tumori; 1990 Feb 28; 76(1):58-60. PubMed ID: 2321275
    [Abstract] [Full Text] [Related]

  • 9. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
    Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L.
    Oncology; 1996 Feb 28; 53(4):263-8. PubMed ID: 8692528
    [Abstract] [Full Text] [Related]

  • 10. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Feb 28; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 11. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
    Lissoni P.
    Pathol Biol (Paris); 2007 Feb 28; 55(3-4):201-4. PubMed ID: 17446010
    [Abstract] [Full Text] [Related]

  • 12. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
    Lissoni P, Meregalli S, Fossati V, Paolorossi F, Barni S, Tancini G, Frigerio F.
    Tumori; 1994 Dec 31; 80(6):464-7. PubMed ID: 7900237
    [Abstract] [Full Text] [Related]

  • 13. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
    Lissoni P, Barni S, Tancini G, Mainini E, Piglia F, Maestroni GJ, Lewinski A.
    Oncology; 1995 Dec 31; 52(2):163-6. PubMed ID: 7854778
    [Abstract] [Full Text] [Related]

  • 14. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 Dec 31; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 15. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P, Mandalà M, Brivio F.
    Eur Urol; 2000 Jul 31; 38(1):115-8. PubMed ID: 10859453
    [Abstract] [Full Text] [Related]

  • 16. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
    Lissoni P, Brivio F, Ardizzoia A, Tancini G, Barni S.
    Tumori; 1993 Dec 31; 79(6):401-4. PubMed ID: 8171739
    [Abstract] [Full Text] [Related]

  • 17. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
    Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Paolorossi F, Brivio F, Perego M, Tancini G, Conti A, Maestroni G.
    Tumori; 1992 Dec 31; 78(6):383-7. PubMed ID: 1297233
    [Abstract] [Full Text] [Related]

  • 18. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug 31; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 19. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Aug 31; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
    Barni S, Lissoni P, Ardizzola A, Vigoré L, Vezzo R, Rescaldani R, Tancini G.
    Tumori; 1993 Oct 31; 79(5):343-6. PubMed ID: 8116079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.